Skip to main content

Cognition Therapeutics, Inc. (CGTX)

Cognition Therapeutics will go public soon, but the exact IPO date is still unknown.
Stock Price: Pending
IPO price not available yet
Chart not available yet
Market Capn/a
Revenue (ttm)n/a
Net Income (ttm)-9.42M
Shares Outn/a
EPS (ttm)n/a
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volumen/a
Openn/a
Previous Closen/a
Day's Rangen/a
52-Week Rangen/a
Betan/a
Analystsn/a
Price Targetn/a
Est. Earnings Daten/a

About CGTX

Cognition Therapeutics is a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Since our inception, we have collaborated and worked closely with key healthcare organizations and thought leading institutions in the field of degenerative diseases to develop and advance our therapeutic candidates. To date we have been awarded approximately $168.4 million in grants and financia...

IndustryBiological Products
IPO DatePending
CEOLisa Ricciardi
Employees20
Stock ExchangeNASDAQ
Ticker SymbolCGTX
Full Company Profile

Financial Performance

Financial Statements

News

Alzheimer's biotech Cognition Therapeutics files for a $50 million IPO

Cognition Therapeutics, a Phase 2 biotech developing small molecule therapies for Alzheimer's and other CNS diseases, filed on Monday with the SEC to raise up to $50 million in an initial public offering.

2 months ago - NASDAQ

Cognition Therapeutics IPO Registration Document (S-1)

Cognition Therapeutics, Inc. has filed to go public with an IPO on the NASDAQ.

2 months ago - SEC